Janet Napolitano - May 30, 2025 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Stock symbol
VIR
Transactions as of
May 30, 2025
Transactions value $
-$16,149
Form type
4
Date filed
6/2/2025, 07:26 PM
Previous filing
Feb 25, 2025
Next filing
Jun 13, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Napolitano Janet Director C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO /s/ Vanina de Verneuil, Attorney-In-Fact 2025-06-02 0001821008

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +8K +68.87% $0.00 19.6K May 30, 2025 Direct F1, F2
transaction VIR Common Stock Sale -$16.1K -3.2K -16.31% $5.05 16.4K Jun 2, 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +16K $0.00 16K May 30, 2025 Common Stock 16K $4.94 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2 The RSUs will vest in full on May 30, 2026.
F3 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2024.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.845 to $5.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The shares subject to the stock option will vest and become exercisable in full on May 30, 2026.